Mentice ABOSTO:MNTC 72 EBIT per Share is kr-0.62 as of Mar. 2026. GuruFocus rates OSTO:MNTC with a GF Score™ of 72/100 and a GF Value™ of kr26.03 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 687 Medical Devices & Instruments companies, Mentice AB ranks worse than 69.29% on this metric.
Mentice AB's EBIT per Share for the
three
months ended in Mar. 2026 was kr-0.55.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr-0.62.
During the past 3 years, the average EBIT per Share Growth Rate was -4.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 16.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Mentice AB's EBIT per Share or its related term are showing as below:
OSTO:MNTC'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -4.7 Med: 16.35 Max: 72.8
Current: -4.7
During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of Mentice AB was 72.80% per year. The lowest was -4.70% per year. And the median was 16.35% per year.
OSTO:MNTC's 3-Year EBIT Growth Rate is ranked worse than 69.29% of 687
companies
in the Medical Devices & Instruments industry
Industry Median: 9.4
vs OSTO:MNTC: -4.70
Mentice AB's EBIT for the
three
months ended in Mar. 2026 was kr-15.3 Mil.
Mentice AB (OSTO:MNTC) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Mentice AB EBIT per Share Related Terms
Mentice AB EBIT per Share Historical Data
* Premium members only.
The historical data trend for Mentice AB's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.62
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mentice AB (OSTO:MNTC) has a EBIT per Share of kr-0.62 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Mentice AB and its competitors. According to the industry distribution chart, Mentice AB ranks #476 out of 687 companies in the Medical Devices & Instruments industry, placing it in the top 69.3%.
Is Mentice AB's EBIT per Share too high?
Mentice AB's current EBIT per Share is kr-0.62. Based on the distribution chart, Mentice AB ranks #476 out of 687 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Mentice AB has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mentice AB's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Mentice AB ranks #476 out of 687 companies for EBIT per Share. This places Mentice AB in the lower half of its industry. The industry median EBIT per Share is 9.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.40, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Mentice AB and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mentice AB's current EBIT per Share is kr-0.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mentice AB stock overvalued right now?
Based on GuruFocus' analysis, Mentice AB (OSTO:MNTC) is currently considered Possible Value Trap. The stock's GF Value™ is kr26.03, compared to a current price of kr13.30 — trading 48.9% below its estimated fair value. The current EBIT per Share is kr-0.62. Mentice AB's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Mentice AB (OSTO:MNTC), the current EBIT per Share is kr-0.62 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mentice AB (OSTO:MNTC) Overvalued in 2026?
Based on GuruFocus' analysis, Mentice AB stock appears to be undervalued.
The current stock price of kr13.30 is trading 48.9% below its estimated GF Value™ of kr26.03.
GuruFocus considers Mentice AB to be Possible Value Trap.
Key valuation signals for OSTO:MNTC:
EBIT per Share: kr-0.62
GF Value™: kr26.03 vs. price of kr13.30 (48.9% below fair value)
No single metric tells the full story. See the OSTO:MNTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mentice AB is a provider of software and hardware simulation solutions for image guided interventional therapies, offering proficiency based simulation solutions that help healthcare professionals acquire, retain, and enhance procedural skills, improving productivity and outcomes. Its solutions are scientifically validated and developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are covered. Mentice operates in two segments: Medical Device Industry (MDI), providing end-to-end solutions supporting development and launch of interventional therapies, and Healthcare Systems (HCS). Product areas include Mentice VIST, Physical Sim, Mentice Live, and Ankyras. It operates in EMEA, APAC, and the Americas.
72GF Score
Get the complete analysis for OSTO:MNTC
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MNTC has been successfully added to your 
